ZYME
Zymeworks Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.88B
P/E Ratio
—
EPS
$-1.37
Beta
1.19
52W High
$29.75
52W Low
$11.02
50-Day MA
$25.72
200-Day MA
$21.92
Dividend Yield
—
Profit Margin
-126.30%
Forward P/E
25.64
PEG Ratio
0.00
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $81.26M |
| Gross Profit (TTM) | $-54.46M |
| EBITDA | $-107.79M |
| Operating Margin | -1957.00% |
| Return on Equity | -42.00% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $1.08 |
| Book Value | $3.60 |
| Price-to-Book | 11.52 |
| Price-to-Sales (TTM) | 23.19 |
| EV/Revenue | 18.91 |
| EV/EBITDA | 0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -91.10% |
| Shares Outstanding | $73.02M |
| Float | $68.09M |
| % Insiders | 1.27% |
| % Institutions | 98.98% |
Historical Volatility
HV 10-Day
25.00%
HV 20-Day
49.53%
HV 30-Day
45.58%
HV 60-Day
45.55%
HV Rank
63.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($40.15 target)
2
Strong Buy12
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026